Person: ÇİÇEK, FATİH
Loading...
Email Address
Birth Date
7 results
Search Results
Now showing 1 - 7 of 7
Publication Infliximab therapy in an infant with Netherton Syndrome(Wiley, 2021-04-22) Çiçek, Fatih; Çekiç, Şükrü; Kılıç, Sara Şebnem; ÇİÇEK, FATİH; ÇEKİÇ, ŞÜKRÜ; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik İmmünoloji Anabilim Dalı.; 0000-0002-9574-1842; 0000-0001-8571-2581; 0000-0001-7348-7081; AAH-1658-2021; JKI-5906-2023; L-1933-2017We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6 months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12 months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.Publication The impact of the SARS-CoV-2 pandemic in PID patients receiving ig replacement therapy(Springer, 2021-01-15) Çekiç, Şükrü; Çiçek, Fatih; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; ÇİÇEK, FATİH; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/İmmünoloji ve Romatoloji Anabilim Dalı; 0000-0002-9574-1842; 0000-0001-7348-7081; 0000-0001-8571-2581; L-1933-2017; AAH-1658-2021; JMD-8408-2023Publication Superb microvascular imaging in assessment of synovitis and tenosynovitis in juvenile idiopathic arthritis(Lippincott Williams & Wilkins, 2021-03-01) Kandemirli, Sedat Giray; Çicek, Fatih; Erdemli Gürsel, Başak; Bilgin, Cem; Kiliç, Sara Sebnem; Yazıcı, Zeynep; Çicek, Fatih; ÇİÇEK, FATİH; Erdemli Gürsel, Başak; ERDEMLİ GÜRSEL, BAŞAK; Bilgin, Cem; BİLGİN, CEM; Kiliç, Sara Sebnem; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Yazıcı, Zeynep; YAZICI, ZEYNEP; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; 0000-0001-7348-7081; 0000-0001-8571-2581; AAH-1658-2021; HHS-7433-2022; JKI-5906-2023; AAH-6568-2021The aim of this study is to evaluate the diagnostic utility of superb microvascular imaging (SMI) in assessment of synovitis/tenosynovitis in juvenile idiopathic arthritis in comparison to power Doppler ultrasound. Thirty juvenile idiopathic arthritis cases with active clinical findings and ultrasound features of effusion and/or tenosynovitis were further imaged with power Doppler and SMI. For classification of synovial inflammation, a semiquantitative scale (4 points) adopted by Outcome Measures in Rheumatology was used.A total of 35 knee, 2 hip, 2 ankle, 2 wrist, 2 elbow joints, and 6 flexor hallucis longus/tibialis posterior tenosynovitis were assessed. In knee joint, power Doppler and SMI scales were the same for 23 (65.7%) joints, SMI upgraded scale from 0 to 2 in single joint (2.9%); 1 to 2 (14.3%) in 5 joints; and 2 to 3 (17.1%) in 6 joints. For other joints, power Doppler and SMI scales were the same for 5 (62.5%) joints. Superb microvascular imaging upgraded scale from 1 to 2 (25%) in 2 joints and 1 to 3 (12.5%) in a single joint. For flexor hallucis longus/tibialis posterior tenosynovitis, power Doppler and SMI scales were the same for two cases (33.3%). Superb microvascular imaging upgraded scale from 0 to 2 in two cases (33.3%); and 2 to 3 (33.3%) in 2 cases. There was no case of SMI scale downgraded compared with power Doppler scale.Superb microvascular imaging is a feasible technique in the assessment of synovial inflammation and tenosynovitis in juvenile idiopathic arthritis. Superb microvascular imaging has higher sensitivity compared with power Doppler ultrasound in depiction of increased vascularity.Publication The impact of the Covid-19 pandemic in adolescents with asthma(Korean Acad Medical Sciences, 2021-12-20) Çekiç, Şükrü; Karali, Zuhal; Çiçek, Fatih; Canıtez, Yakup; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; KARALI, ZUHAL; ÇİÇEK, FATİH; CANITEZ, YAKUP; SAPAN, NİHAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Alerji Bilim Dalı; 0000-0002-9574-1842; 0000-0001-7348-7081; 0000-0001-8929-679X; JKI-5906-2023; AAH-1789-2021; L-1933-2017; CZC-9168-2022; FUI-8766-2022Background: The coronavirus disease 2019 (COVID-19) pandemic is affecting people at any age and there is limited information about the effect of the COVID-19 pandemic on quality of life (QoL) in adolescents with asthma. In the present study, it was aimed to assess the attitudes of adolescents with asthma toward the COVID-19 pandemic and determine the effects of the pandemic on their QoL. Methods: In total, 125 adolescents with asthma and 98 healthy adolescents participated in the present study. The questionnaire form consisted of three parts. In the first part, all the participants were asked whether they complied with the protective measures against COVID-19. The second part included questions for measuring the participants' level of concern about COVID-19, while the third part consisted of EUROHIS-QOL 8. Results: The patient and control groups were similar in terms of the female/male ratio (55/70 and 48/50, respectively) and mean participant age (14.6 +/- 2 and 15.1 +/- 1.65 years, respectively) (P = 0.459 and P = 0.062, respectively). The prevalence of COVID-19 in the patients (n = 2, 1.6%) was lower than that in the controls (n = 6, 6.1%); however, the difference was not statistically significant (P = 0.142). The total EUROHIS-QOL score was significantly lower in the patients (31.2 +/- 6.7) than in the controls (33.7 +/- 4.4) (P < 0.001). The total QoL scores of asthmatic adolescents without other allergic disease (31.4 +/- 6.7) was also lower than those of the controls (33.7 +/- 4.4) (P = 0.009). Treatment disruption was significantly more common in patients who received subcutaneous immunotherapy (n = 20, 48.8%) than in those who did not (n = 8, 9.5%) (P < 0.001). Moreover, the patients had lower EUROHIS-QOL scores in the overall QoL, general health, finance, and home domains. Conclusion: Our results indicate that the mean QoL score of asthmatic adolescents during COVID-19 pandemic is lower than in the healthy population. Disruption in their treatment was most common in patients with asthma who were receiving subcutaneous immunotherapy.Publication Knowledge levels of mothers of asthmatic children about asthma(Dr Behcet Uz Cocuk Hastaliklari Ve Cerrahisi, 2020-01-01) Çekiç, Şükrü; ÇEKİÇ, ŞÜKRÜ; Canıtez, Yakup; CANITEZ, YAKUP; Küçüker, Hakan; KÜÇÜKER, HAKAN; Karali, Yasin; KARALI, YASİN; Çiçek, Fatih; ÇİÇEK, FATİH; Sapan, Nihat; SAPAN, NİHAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; 0000-0002-9574-1842; L-1933-2017Objective: Compliance of the family with asthma treatment is one of the main factors determining the success of treatment. This study aimed to investigate the knowledge level of the mothers with asthmatic children about symptoms, diagnosis and treatment of asthmaMethod: A questionnaire consisting of 42 questions was used in the study. The questionnaire was composed of questions prepared by us and adapted from a validated asthma knowledge level questionnaire. Each correct answer was evaluated as 2.38 points. Those receiving 67.7 points above were considered sufficient.Results: 323 mothers of children with asthma were included in the study. None of the mothers answered all the questions correctly among. The total mean score of the mothers was 57.8 +/- 11.9 (median: 58.5, minimum: 26.8, maximum: 87.8). The median scores of the mothers who graduated from university (median: 65.9, minimum: 36.6, maximum: 85.4) was higher than those who graduated from primary school (median: 53.7, minimum: 29.3, maximum: 87.8), middle school (median: 58.5, minimum: 29.3, maximum: 78) and high school (median: 61, minimum: 26.8, maximum: 80.5) (p<0.001, p<0.001 and p=0.003). The median score of working mothers (median: 65.9, minimum: 34.1, maximum: 87.8) was higher than those who were housewives (median: 56.1, minimum: 26.8, maximum: 87.8) (p<0.001). The median score of mothers who breastfed for more than six months (median: 61, minimum: 29.3, maximum: 87.8) was higher compared to those who breastfed less than six months (median: 56.1, minimum: 26.8, maximum: 85.4) (p=0.005).Conclusion: Education levels of the mothers and being a working mother were significant factors affecting the level of asthma knowledge among mothers.Publication Three different faces of taci mutations(Wiley, 2020-04-08) Çekic, Şükrü; Çicek, Fatih; Karalı, Yasin; Görükmez, Orhan; Eren, Erdal; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; ÇİÇEK, FATİH; KARALI, YASİN; EREN, ERDAL; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik Alerji ve Klinik İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinolojisi Anabilim Dalı.; 0000-0002-9574-1842; 0000-0001-7348-7081; 0000-0002-1684-1053; 0000-0001-8571-2581; 0000-0002-1245-4232; AAH-1658-2021; JPK-3909-2023; JKI-5906-2023; L-1933-2017; FFS-1974-2022Publication The effect of allergen immunotherapy on the development of new sensitization in children(Aves, 2021-07-01) Çekiç, Şükrü; Canıtez, Yakup; Çiçek, Fatih; Ocakoğlu, Gökhan; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; CANITEZ, YAKUP; ÇİÇEK, FATİH; OCAKOĞLU, GÖKHAN; SAPAN, NİHAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Alerji Bilim Dalı; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; 0000-0002-9574-1842; 0000-0002-1114-6051; 0000-0001-8929-679X; 0000-0001-7348-7081; L-1933-2017; AAH-5180-2021; AAH-1789-2021; JKI-5906-2023; FUI-8766-2022Aim: The protective effect of allergen immunotherapy against a new allergic sensitization is controversial. This study aimed to investigate the effect of allergen immunotherapy on new allergic sensitization in children.Materials and Methods: The study included 50 patients who received immunotherapy for at least 3 years, and whose skin prick tests were repeated at intervals of at least 3 years (31 patients for house dust mite immunotherapy, 19 patients for pollen immunotherapy), and 69 controls with similar characteristics.Results: The number of patients who developed a new sensitization was similar both in the groups of patients who received house dust mite and pollen immunotherapy, and the control group. There was no significant difference between the first and last skin prick tests of the patients who received house dust mite and pollen immunotherapy; however, in the control groups, a significant increase in sensitivity to tree pollens (n = 2, 5.4%; n = 8, 21.6%) and weed pollens (n = 7, 26.9%; n = 14, 53.8%) was detected (P = .031 and P = .039). While allergen sensitivities in the first tests of the pollen immunotherapy group and the control group were similar, weed pollen sensitivity was significantly higher in the last tests of the control group (n = 14, 53.8%; n = 4, 21.1%, P = .027). It was determined that the presence of weed pollen sensitization (OR: 8.1, 95% CI: 1.5-42.4) and having asthma (OR: 3.5, 95% CI:1.3-10.8) increases the risk of new sensitization in all groups.Conclusion: Allergen immunotherapy has been found to protect against new sensitization to tree and weed pollens. However, this effect was insignificant in the multivariate analysis. Weed pollen sensitization and the presence of asthma are related to the development of new sensitization.